BRIEF-Bristol-Myers Squibb Says Opdivo Plus Chemotherapy Significantly Improves Pathologic Complete Response In Patients With R
BRIEF-Bristol-Myers Squibb Says Opdivo Plus Chemotherapy Significantly Improves Pathologic Complete Response In Patients With R
* NEOADJUVANT OPDIVO (NIVOLUMAB) PLUS CHEMOTHERAPY SIGNIFICANTLY IMPROVES PATHOLOGIC COMPLETE RESPONSE IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER IN PHASE 3 CHECKMATE -816 TRIAL
* BRISTOL-MYERS SQUIBB - NEARLY A QUARTER OF PATIENTS WHO RECEIVED OPDIVO PLUS CHEMOTHERAPY SHOWED NO EVIDENCE OF CANCER CELLS IN TISSUE REMOVED
* BRISTOL-MYERS SQUIBB - OPDIVO PLUS CHEMOTHERAPY WAS WELL TOLERATED; SHOWED CONSISTENT IMPROVEMENTS IN PCR
* BRISTOL-MYERS SQUIBB - OPDIVO PLUS CHEMOTHERAPY ALSO DEMONSTRATED IMPROVEMENTS IN KEY SECONDARY ENDPOINTS, INCLUDING MAJOR PATHOLOGICAL RESPONSE
* BRISTOL-MYERS SQUIBB - THREE CYCLES OF OPDIVO PLUS CHEMOTHERAPY WERE ASSOCIATED WITH A TOLERABLE SAFETY PROFILE; NO NEW SAFETY SIGNALS WERE OBSERVED
* SURGERY WAS RARELY CANCELED DUE TO ADVERSE EVENTS, ONLY AFFECTING TWO PATIENTS IN EACH ARM OF TRIAL
* BRISTOL-MYERS SQUIBB - NUMBER OF PATIENTS WHOSE TUMORS WERE COMPLETELY RESECTED (R0) WAS HIGHER WITH OPDIVO PLUS CHEMOTHERAPY VERSUS. CHEMOTHERAPY
* BRISTOL-MYERS SQUIBB - RATES OF SURGERY-RELATED ADVERSE EVENTS WERE SIMILAR BETWEEN TWO TREATMENT ARMS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
April 10 (Reuters) - Bristol-Myers Squibb Co :
* NEOADJUVANT OPDIVO (NIVOLUMAB) PLUS CHEMOTHERAPY SIGNIFICANTLY IMPROVES PATHOLOGIC COMPLETE RESPONSE IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER IN PHASE 3 CHECKMATE -816 TRIAL
* BRISTOL-MYERS SQUIBB - NEARLY A QUARTER OF PATIENTS WHO RECEIVED OPDIVO PLUS CHEMOTHERAPY SHOWED NO EVIDENCE OF CANCER CELLS IN TISSUE REMOVED
* BRISTOL-MYERS SQUIBB - OPDIVO PLUS CHEMOTHERAPY WAS WELL TOLERATED; SHOWED CONSISTENT IMPROVEMENTS IN PCR
* BRISTOL-MYERS SQUIBB - OPDIVO PLUS CHEMOTHERAPY ALSO DEMONSTRATED IMPROVEMENTS IN KEY SECONDARY ENDPOINTS, INCLUDING MAJOR PATHOLOGICAL RESPONSE
* BRISTOL-MYERS SQUIBB - THREE CYCLES OF OPDIVO PLUS CHEMOTHERAPY WERE ASSOCIATED WITH A TOLERABLE SAFETY PROFILE; NO NEW SAFETY SIGNALS WERE OBSERVED
* SURGERY WAS RARELY CANCELED DUE TO ADVERSE EVENTS, ONLY AFFECTING TWO PATIENTS IN EACH ARM OF TRIAL
* BRISTOL-MYERS SQUIBB - NUMBER OF PATIENTS WHOSE TUMORS WERE COMPLETELY RESECTED (R0) WAS HIGHER WITH OPDIVO PLUS CHEMOTHERAPY VERSUS. CHEMOTHERAPY
* BRISTOL-MYERS SQUIBB - RATES OF SURGERY-RELATED ADVERSE EVENTS WERE SIMILAR BETWEEN TWO TREATMENT ARMS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透4月10日電-百時美施貴寶(Bristol-Myers Squibb Co.)：*在3期CHECKMate-816試驗中，新輔助藥物Opdivo(Nivolumab)加化療顯著改善了可切除非小細胞肺癌患者的病理完全反應*百時美施貴寶(Bristol-Myers Squibb)-近四分之一接受Opdivo加化療的患者顯示，沒有證據表明切除的組織中有癌細胞*百時美施貴寶(Bristol-Myers Squibb-Opdivo)加化療耐受性良好；PCR顯示持續改善*百時美施貴寶(Bristol-Myers Squibb-Opdivo)加化療也顯示出關鍵次要終點的改善，包括主要病理反應*百時美施貴寶(Bristol-Myers Squibb)-Opdivo加化療的三個週期與可耐受的安全性相關；沒有觀察到新的安全信號*手術很少因不良事件而取消，試驗的每一臂隻影響兩名患者*百時美施貴寶(Bristol-Myers Squibb)-接受Opdivo加化療的腫瘤完全切除(R0)的患者數量高於接受Opdivo加化療的患者數量。化療*百時美施貴寶(Bristol-Myers Squibb)-兩個治療部門與手術相關的不良事件發生率相似Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧